We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Membrane-Bound Enzyme Linked to Plaque Formation in Mouse Atherosclerosis Model

By LabMedica International staff writers
Posted on 21 Jul 2015
Cardiac disease researchers working with a mouse model of atherosclerosis have found that that a specific membrane bound enzyme has the potential to inhibit build-up of plaque and reduce risk of heart attack or stroke.

Investigators at the University of Michigan (Ann Arbor, USA) worked with the apolipoprotein E-deficient (ApoE-deficient) mouse model of atherosclerosis to examine the role of the enzyme CD39 (ectonucleotide tri(di)phosphohydrolase-1 or ENTPD1) in the process of plaque formation. More...
This enzyme metabolizes locally released, intravascular ATP and ADP, thereby eliminating these pro-thrombotic and pro-inflammatory signaling molecules.

The investigators reported in the June 29, 2015, online edition of the Journal of Clinical Investigation that when animals fed a high-fat diet were compared, it was seen that ApoE-deficient mice that also lacked CD39 had a plaque burden that was markedly increased along with circulating markers of platelet activation. CD39 was prominently expressed in stable blood flow regions and was diminished in areas subjected to disturbed flow. Thus, CD39 activation followed the pattern of plaque formation.

In mice, disturbed blood flow as the result of partial carotid artery ligation rapidly suppressed endothelial CD39 expression. Moreover, unidirectional laminar shear stress induced protective CD39 expression in human endothelial cells.

“Better lifestyles and improved treatments have slowed the rates of death from atherosclerosis, but if CD39 proves to be as critical a factor in humans as in mice, it would be a major step forward in understanding heart disease,” said senior author Dr. David Pinsky, professor of cardiology at the University of Michigan.

Related Links:

University of Michigan



New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.